Moreover, anti-EGFR antibodies have demonstrated high activity in patients with metastatic BRAF class 3–mutated CRC while showing low activity in those harboring class 2 mutations.6,20 Notably, other potential targets reported to be active in some cases of BRAF class 3–mutated tumors, such as MET, and erlotinib off-target effects that may contribute to cell growth inhibition were not explored in this study and may be object of further investigation in future research.6 This evidence concerns the gene EGFR and colorectal carcinoma.